Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Mulls “Fast Track” Approach For Priority Review Voucher Eligibility

Executive Summary

FDA should consider setting up a process to pre-determine whether a product being developed for a neglected tropical disease will qualify for a priority review voucher, BIO Ventures for Global Health VP-Strategy & Operations Wendy Taylor said Dec. 12 at a public hearing convened by the agency
Advertisement

Related Content

Priority Review Vouchers: Coartem And The Importance Of Perceptions
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility
FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility
Advertisement
UsernamePublicRestriction

Register

PS050466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel